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The long-term goal of this study is to investigate if human monocytes treated
with Ebola virus (EBOV) virus-like particles (VLPs) supplemented with a
constitutively active form of retinoic acid-inducible gene 1 (caRIG-I) induce an
inflammatory response in vitro. RIG-I is a cytosolic pattern recognition receptor
(PRR) that is primarily responsible for the recognition of cells that have been
infected with a virus and for the induction of type I interferon response
(Rehwinkel & Gack, 2020). VLPs are molecules that mimic the structure, form, and
size of a virus particle but lack the viral genome resulting in a virion that can
infect and stimulate an immune response without causing disease. In general,
these virions are safe enough to be used within vaccines to assist in the
prevention of infectious diseases. We hypothesize that addition of caRIG-I to a
vaccine would induce the production of interferon to promote a more effective and
efficient immune response. The expression of EBOV VP40 in human embryonic kidney
293T cells induces the production of VLPs secreted into the cell media. If the
EBOV glycoprotein is concurrently expressed, VLPs studded with the attachment
glycoprotein are produced. Expression of a chimeric wtRIG-I VP40 matrix protein
and a chimeric nonfunctional mutant (mu)RIG-I VP40 matrix protein produce VLPs
containing the wild type and muRIG-I, respectively. Expression of
-lactamase-VP40 protein along with either WtRIG-I VP40, muRIG-I VP40, or FLAG
VP40 proteins in transfected 293T cells produced -lactamase containing VLPs. A
-lactamase assay was used to quantitate relative amounts of VLPs. Human
monocytes treated with VLPs containing caRIG-I are expected to produce interferon
enhancing the immune response. In this study, we produced and quantitated wtRIG-I
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Abstract
The long-term goal of this study is to investigate if human monocytes treated with Ebola
virus (EBOV) virus-like particles (VLPs) supplemented with a constitutively active form of
retinoic acid-inducible gene 1 (caRIG-I) induce an inflammatory response in vitro. RIG-I is a
cytosolic pattern recognition receptor (PRR) that is primarily responsible for the recognition of
cells that have been infected with a virus and for the induction of type I interferon response
(Rehwinkel & Gack, 2020). VLPs are molecules that mimic the structure, form, and size of a
virus particle but lack the viral genome resulting in a virion that can infect and stimulate an
immune response without causing disease. In general, these virions are safe enough to be used
within vaccines to assist in the prevention of infectious diseases. We hypothesize that addition of
caRIG-I to a vaccine would induce the production of interferon to promote a more effective and
efficient immune response. The expression of EBOV VP40 in human embryonic kidney 293T
cells induces the production of VLPs secreted into the cell media. If the EBOV glycoprotein is
concurrently expressed, VLPs studded with the attachment glycoprotein are produced.
Expression of a chimeric wtRIG-I VP40 matrix protein and a chimeric nonfunctional mutant
(mu)RIG-I VP40 matrix protein produce VLPs containing the wild type and muRIG-I,
respectively. Expression of -lactamase-VP40 protein along with either WtRIG-I VP40, muRIGI VP40, or FLAG VP40 proteins in transfected 293T cells produced -lactamase containing
VLPs. A -lactamase assay was used to quantitate relative amounts of VLPs. Human monocytes
treated with VLPs containing caRIG-I are expected to produce interferon enhancing the immune
response. In this study, we produced and quantitated wtRIG-I VP40 + GP, muRIG-I VP40 + GP,
FLAG VP40 + GP, and wtRIG-I VP40 + GPF88A VLPs. We also treated human monocytes
with these VLPs. Future studies will test whether the treated monocytes were activated and
induce interferon.
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Introduction
The Ebola virus (EBOV) is a member of the Filoviridae family that causes severe
hemorrhagic fevers in infected humans. EBOV is a deadly virus as it has caused an average
fatality rate of 50% in documented outbreaks and has even reached a 90% fatality rate.
The EBOV productively infects several cell types including antigen-presenting cells
(APCs). An example of an APC is a dendritic cell which expresses receptors that sense foreign
cells and molecules. Upon detection of a foreign molecule or cell, the APC receptors will, in
some cases, bind to the antigen (a molecule or cell that can induce an immune response) and
internalize it. Immature dendritic cells will internalize the pathogen and transport it to the
draining lymphoid organ such as a lymph node. When dendritic cells detect a pathogen, they will
release proinflammatory cytokines which induce the maturation of the dendritic cell. Upon
arrival to the lymphoid organ, the mature dendritic cell will present the antigen to T cells which
will activate the adaptive immune response which in turn will eliminate the invading pathogen.
When EBOV infects these dendritic cells, it causes the dendritic cells to become deregulated and
thus allows the EBOV to replicate and infect more tissues throughout the body (Martinez et al.,
2010).
Virus-like particles (VLPs) of Ebola virus have the same appearance as the infectious
virus, however they are devoid of any genetic material. VLPs contain the EBOV VP40 and spike
(glycoprotein) proteins. The expression of the EBOV matrix protein, VP40, induces the
production of VLPs which are long, cylindrical polymers of VP40 covered by a membrane. By
co-transfecting a glycoprotein expression-plasmid with a VP40 expression-plasmid into human
293T cells, the translated glycoprotein will be expressed on the outer membrane surface of the
VLP and will be used for cell adhesion and entry (Watanabe et al., 2004).
The Ebola VLPs express the same morphology as the authentic Ebola virus but do not
contain any genetic information. Without this genetic information, the VLPs are unable to
replicate upon infection and could therefore, in comparison to attenuated vaccines, be utilized as
a safer vaccination option for the general population. Replication-incompetent Ebola VLPs
would be able to infect targeted dendritic cells. VLP entry into dendritic cells (DC) could
stimulate the maturation of the DC including their ability to present viral antigens to
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lymphocytes. The direct activation of dendritic cells using modified VLPs could enhance
efficiency of the adaptive immune response against the virus (Chroboczek et al., 2014).
Adjuvants are used as vaccine additives to enhance the immune response towards the
specific pathogen in the vaccine. VLP vaccines usually need to use an adjuvant because they
contain minimal proportions of stimulatory (Donaldson et al., 2018). For the purpose of this
study, retinoic acid-inducible gene I (RIG-I) will be used as an adjuvant. RIG-I is a cytosolic
pattern recognition receptor (PRR) that is able to recognize cells that have been infected with a
virus that contains a double stranded RNA genome (Luo, 2014). RIG-I induces the production of
anti-viral type I interferon (IFN) cytokines that help activate the immune system. For example,
IFN helps promote the killing of virus-infected cells by CD8 cytotoxic T cells, and it also
enhances the responses of adaptive and innate immune systems towards viral infections.
Isolated human monocytes will be treated with VLPs containing RIG-I and VLPs that do
not contain RIG-I. To determine the effectiveness of RIG-I in human cells, the production of
(type 1) interferon will be examined.
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Materials and Methods
Cell Lines and Plasmids
Human embryonic kidney 293T cells were used for transfections and were grown in
Dulbecco’s Modified Eagle Medium (DMEM) that was supplemented with 5-10% fetal bovine
serum (FBS), penicillin, streptomycin, L-glutamine, and amphotericin. The DNA plasmids used
in this study were -lactamase-VP40, FLAG-VP40, 2XCARD-RIG-I-VP40, mutant
L58A(mu)RIG-I-VP40, glycoprotein, and glycoprotein F88 (GPF88A) expression plasmids.
Ampicillin Plates
Ampicillin agar plates selected bacteria that were transformed with plasmids expressing
ampicillin resistance. Ampicillin agar packet (Invitrogen, Waltham, MA) contents was added to
200 mL of distilled water and microwaved to melt it. Once melted, 10 mL of the agar was
pipetted into each petri dish and was placed at 4C to solidify.
Quick Transformation of two plasmids
Two ampicillin plates were placed at 37C for 10 minutes to warm. A microfuge tube
was labeled “GP” and another microfuge tube was labeled “wtRIG-I VP40”. Stock DNA
samples for each were obtained and spun in a centrifuge for 30 seconds at 2000Xg. After the
DNA was separated from any possible bacterial contamination, 1 L of each DNA sample was
pipetted into their respective microfuge tube. Next, 3 L of competent cells were also pipetted
into each tube and the mixture was placed in 4C for 1 minute exactly. The tubes were then
placed in a water bath set at 42C for 1 minute and then on ice for 1 minute. 200 L of LB media
was pipetted into each tube. The warmed ampicillin plates were labeled “GP” and “wtRIG-I
VP40”. Each microfuge tube’s contents were poured onto their respective ampicillin plates and
were spread evenly across the surface. The plates were placed in 37C for 24 hours.
Two sterile LB media flasks, 150 mL each were used. One LB media flask was labeled
“GP” and the other was labeled “wtRIG-I VP40.” 150 L of Amp (“A”) was added to each flask
for a concentration of 1 g/mL. Using a pipette tip, one colony from each of the grown plates
that were stored at 4C was transferred to its respective LB media flask and was placed in 37C
on a rocking machine for aerated growth to occur.
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Maxi-Preps
The contents of each LB media flask were added to its own conical tube. These contents
were spun down in a centrifuge for 10 minutes at 6,000 × g at 4C to form a pellet. Bacterialamplified DNA was harvested using Maxi-Prep kits (QIAGEN, Germantown, MD). From this
kit, the RNAse A solution was added to buffer P1, and LyseBlue was also added to buffer P1.
The pellets that were formed after centrifugation were resuspended using 8 mL of the P1 buffer
until the solution was resuspended and homogenous. 8 mL of buffer P2 was added to each
sample, and 8 mL of buffer P3 was also added to each tube. Each solution was poured onto their
own QIAfilter Maxi cartridge filter and incubated for 10 minutes at RT. Two 50 mL screwcap
tubes were obtained and labeled “GP” and “wtRIG-I,” and 5 mL of BB buffer was added to each
tube. A vacuum was prepared. Tube extenders were attached to mini columns. The vacuum was
started and each of the DNA solutions was poured into their own tube extender. Meanwhile, 24
mL of ethanol was added to the PE buffer bottle. In each tiny vacuum tube, 700 L of ETR
buffer was added and the vacuum resumed. Once the vacuuming concluded, each tiny column
was placed in the centrifuge and spun at 10,000 × g for 10 minutes. The contents of each tube
was transferred to a new sterile 2 mL tube, and 400 L of EB buffer was added and left to stand
for less than 1 minute to elute the DNA. The tubes were centrifuged for 1 minute at 10,000 × g.
The concentrations of the DNA maxi-preps to be used were checked using a nanodrop
spectrophotometer (Thermo Scientific, Wilmington, DE). For GP DNA, 614 ng/L was
measured with a A260/A280 of 1.91. For wtRIG-I, 59.3 ng/L was measured with a A260/A280
of 1.90.

Transfections of 293T
293T cells were quantitated using a Vi-CELL XR 2.04 counter. There were 5 million
293T cells per 20 mL solution counted. These cells were seeded in 20 new plates at a density of
1 mL cell solution + 10 mL DMEM to each plate and grown at 37C for two days.
The transfections took place in 6 ultracentrifuge tubes. The DNA that was used for this
procedure was FLAG VP40, wtRIG-I VP40, VP40 -lac, GP, GPF88A, and muRIG-I VP40.
Transfections were used to insert a plasmid that expresses RIG-I protein into a mammalian cell
where it would spontaneously produce VLPs containing RIG-I (VLP made using wtRIG-I-VP40
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+ VP40 -lactamase + GP expression plasmids). The maxi-prep DNA was spun down in a
centrifuge at 2000g for 30 seconds. For transfection, solution A was prepared using 1 M CaCl2,
DNA, and sterile water; solution B was prepared using 600 L of 2x Hepes Buffered Saline
(HBS) (seen in Table 1 and 2 below). Solution A was added to each tube and was mixed by
pipetting up and down. Following this, these VLP and solution A mixtures were added dropwise
to solution B over a course of approximately 90 seconds and stirred with the pipette tip. These 6
tubes were left to incubate at room temperature for 30 minutes.
Twelve 293T growing plates (about 70% confluence) were selected to use for
transfection. Two plates for each of the mixtures (transfection mixtures were prepared for two
plates) were labeled according to what DNA they would contain. For each plate, half of each its
respective transfection mixture was added dropwise and was swirled gently to mix the DNA
mixtures with the 293T cells in the plate. All the 12 plates were incubated at 37C.

Table 1. Volumes and mass of DNA added to each plasmid preparation

Table 2. Volumes of solutions added to each plasmid preparation
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Purification of VLPs
Three days following the transfection procedure, the 293T cells and supernatants that
contained VLPs expressing RIG-I were harvested. To separate the VLPs from other supernatant
contents, 6 ultracentrifuge tubes were obtained – 1 tube was labeled “1” signifying the wtRIG-I
VP40 VLP prep, 2 tubes were labeled “2” signifying the GPF88A VLP prep, 2 tubes were
labeled “3” signifying the muRIG-I VP40 VLP prep, and 1 tube was labeled “4” signifying the
FLAG VP40 VLP prep to match identically to the tubes used in the above transfection
procedures as seen in Table 1 and 2 above. In each centrifuge tube, 8 mL of 20% sucrose
solution was added. Spent media containing VLPs from the transfection plates were first spun at
9,000 RPM for 5 minutes at 21C to pellet away cells and 27 mL was then carefully overlayered
onto the sucrose cushion in the ultracentrifuge tube. Furthermore, 5 mL of NTE buffer was used
to wash each transfection plate to recover more VLPs and was then overlayered onto the
supernatant. They were spun in an Optima XPN 100 Ultracentrifuge at 100,000 × g for 2 hours
and 20 minutes to pellet the VLPs. Once the centrifuge had stopped, the supernatant from each
tube was carefully aspirated. 35 mL of NTE buffer was added to each tube to wash the VLP
pellet and recentrifuged. These tubes were stored at 4C and VLPs were resuspended in 150 L
of NTE buffer.

Quantifying VLPs
The VLPs were quantified using the -lactamase assay to assay the relative amounts of
VLPs. A 1:1 (v/v) solution of water and cytobuster was prepared. Fluorocillin was obtained from
the freezer, thawed, and diluted to 5 mM final concentration using the water/cytobuster solution.
In a 96 well, black, clear flat-bottom plate, 50 L of the 5 mM Fluorocillin solution was added to
specified wells. The stored VLP stocks were spun in a centrifuge at 2,000 × g for 30 seconds to
clear aggregates and then resuspended. Specific amounts of VLPs were added to a 96-well plate.
Figure 1 displays an example of the layout of this 96-well microplate. Using the
USB:SpectraMax i3X software (Molecular Devices, San Jose, CA, USA), fluorescence spectra
was taken after certain amounts of time during incubation at room temperature.
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Isolation of Human Monocytes
Approximately 25 mL of blood was obtained from each of two anonymous human blood
donors. These blood samples were added to 50 mL conical tubes. 25 mL of PBS was added to
each tube of blood. Next, 20 15 mL screw cap tubes were filled with 3mL of Ficoll-Hypaque
(Amersham Biosciences, Amersham, United Kingdom) each; of these tubes, 10 were labeled
person 1 and the other 10 were labeled person 2. From each of the blood + PBS samples, 5 mL of
the mixture was used to overlay the Ficoll-Hypaque of the respective subject tubes. These tubes
were centrifuged at 400 × g for 35 minutes at 19C. Maximum acceleration of the centrifuge
was used while the deceleration and brake was turned off. After centrifugation was complete, the
upper layer of plasma was discarded from each tube. The mononuclear immune blood cells
including monocytes within the buffy layer was harvested and added to a sterile centrifuge tube.
PBS was added to make the ratio 3:1. These tubes were centrifuged at 500 × g for 10 minutes at
19C, and the brake was turned back on. Once again, the tubes were removed, and the white
blood cells were observed in a pellet at the bottom of each tube. These cells were aspirated with
a vacuum. MojoSort Buffer 1X (BioLegend, San Diego, California) was then made using 40 mL
of water and 10 mL of 5X MojoSort buffer. The cells as well as the buffer were placed in the
fridge at 4C until sorting.
The MojoSort kit (BioLegend, San Diego, California) was used to isolate human
monocytes by negative selection. The buffy layer pellet containing the human monocytes was
resuspended in 1X MojoSort Buffer created above, Human TruStain FcXTM was added, and this
mixture was allowed to incubate at room temperature for 10 minutes. A Biotin-Antibody cocktail
that contained antibodies linked to biotin was used to bind to all lineages (such as T cells, B
cells, and natural killer cells) except monocytes. This tube was kept on ice for 10 minutes. While
on ice, metal Streptavidin Nanobeads were added to the antibody-coated cells. MojoSort buffer
was once again used to wash all the cells, and the tube was centrifuged at 300 × g for 5
minutes. The supernatant left from the centrifugation process was discarded, and more buffer
was added. This resulting mixture was kept on a MojoSort magnet for 5 minutes, and the tube
was inverted which allowed monocytes not bound by the magnet to elute off and become
separated from all other blood cells. The monocyte-containing supernatants from each individual
blood donor’s sample was collected.
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Monocyte Stimulation Assay
Monocytes were aliquoted into 34 wells of a 96 well plate (10 rows of triplicates, 2 rows
of doublets) at 25,000 monocytes per well (Figure 5 demonstrates this 96-well plate layout).
These monocytes were stimulated with VLP equivalents: 10 L of wtRIG-I VP40, 9.42 L of
muRIG-I VP40, 10.95 L of FLAG VP40, and 10 L of GPF88A. In addition to the VLPs, a
positive control solution of VACV-70 and LPS were added to their own separate triplicate. The
plate was spinoculated for 90 minutes at 2000 × g at 10C to enhance VLP entry and was later
placed in the 37C incubator for the 24-hour stimulation.
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Results
We produced VLPs to examine whether the RIG-I containing VLPs induce IFN
production from treated human monocytes as compared to VLPs that express a mutant
nonfunctional RIG-I. WtRIG-I VP40 + GP, muRIG-I VP40 + GP, FLAG VP40 + GP, and
wtRIG-I VP40 + GPF88A VLPs were successfully produced and quantified using a fluorescence
based -lactamase assay. During the preparation of these VLPs, transfections were spiked with
equivalent amounts of VP40--lactamase expression plasmid. This -lactamase-VP40 enzyme
was incorporated into each VLP produced. The amount of VLPs produced is proportional to the
amount of beta-lactamase assayed. The average -lactamase relative units at a post-incubation
time of 1 hour and 45 minutes for wtRIG-I VP40 was 516177.5, muRIG-I VP40 was 647913,
FLAG VP40 was 559418.5, and GPF88A was 511119.5 (Figure 2). These results demonstrated
higher average -lactamase units for muRIG-I VP40 than others meaning that this VLP provided
higher -lactamase activity within this assay. The -lactamase units obtained for each VLP prep
can be used to determine VLP equivalents for all other future functional assays.
Once we were able to successfully produce and quantify our VLPs, monocytes from two
individual blood donors were isolated and stimulated with the VLPs: wtRIG-I VP40 + GP, muRIGI VP40 + GP, FLAG VP40 + GP, and wtRIG-I VP40 + GPF88A. In addition to the VLPs, these
monocytes were also stimulated with VACV-70 and LPS positive controls. The VLPs and the
positive controls were added in triplicate incubated for 24 hours (Figure 5).
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Discussion
VLPs were produced to test whether RIG-I containing VLPs can induce more interferon
from human monocytes than control VLPs. A -lactamase assay was used to quantify the
relative amounts of each VLP. Results from the beta-lactamase assay show that muRIG-I VP40
+ GP VLPs were shown to have higher -lactamase units (647913) which may mean that this
sample had more VLPs: wtRIG-I VP40 was 516177.5, FLAG VP40 was 559418.5, and GPF88A
was 51119.5. However, the differences in these values could be due to pipetting error.
Statistically, additional -lactamase assays would need to be performed in triplicate to get a
standard error and then a p-value could be calculated to test whether the differences were
statistically significant. The -lactamase units obtained for each of the VLP preps will be used to
determine VLP equivalents.
For the purpose of verifying our results from the -lactamase assay performed in Figure
1, two additional -lactamase assays were performed as seen in Figures 3 and 4. From these
assays, we were able to see that the results obtained from the 1st and 3rd assays were very similar.
However, the 2nd trial of this assay provided varying results with large error bars. The lack of
consistency throughout these results may have been a result of pipetting errors. Further assays
can be performed in the future in order to verify the amounts of each VLP that were quantitated.
The isolated monocytes from two healthy individuals donors were successfully
stimulated with our VLPs: wtRIG-I VP40 + GP, muRIG-I VP40 + GP, FLAG VP40 + GP, and wtRIG-I
VP40 + GPF88A. After incubation, we expected to see that if the monocytes were stimulated by
their VLP treatment, then the monocytes would produce interferon into the supernatant of the
sample. Each individual tube’s supernatant sample would be tested for the interferon through the
use of reporter cells which would emit light upon interferon signaling. This would signify that
the amount of light emitted is equivalent to the amount of interferon signaling that was produced
by these monocytes. We predict that RIG-I containing VLPs (wtRIG-I VP40) would produce
higher interferon signaling which supports the purpose of this study which was to prove that
RIG-I containing VLPs would produce an effective vaccine against EBOV due to its more
immunogenic effects upon interaction with immune cells.
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Figure 1. Layout of 96-well black, clear bottom microplate used during VLP quantification

Description: In a 96-well black, clear flat-bottom plate, 50 L of the 5 mM Fluoricillin solution
was added to 15 wells (5 rows of triplicates shown above). In the row 2 triplicate, 15 L of
(wtRIG-I VP40 + VP40 -lac + GP) was added to each well. In the row 3 triplicate, 15 L of
(wtRIG-I VP40 + VP40 -lac + GPF88A) was added to each well. In the row 4 triplicate, 20 L
of (muRIG-I VP40 + VP40 -lac + GP) was added to each well. In the row 5 triplicate, 30 L of
(VP40 + VP40 -lac + GP) was added to each well. Lastly, in the row 6 triplicate, a blank
solution of PBS/cytobuster-Fluoricillin was added for the purpose of having a control lane.
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Figure 2. 1st Quantification of VLPs using -lactamase assay with relative fluorescence.

Description: A preparation of all VLPs produced in this study, VP40 + GP, muRIG-G VP40 +
GP, wtRIG-I VP40 + GP, and wtRIG-I VP40 + GPF88A were added in 10 L increments to a
black, clear bottom microplate along with a blank solution (PBS/cytobuster-Fluoricillin
solution). The plate was read at a wavelength of 525 nm and an excitation of 495 nm. The plate
was also set to shake on medium speed before the first read for 8 seconds. Fluorescence spectra
was taken above at 105 minutes time post-incubation at room temperature using the
USB:SpectraMax i3X software (Molecular Devices, San Jose, CA, USA). The fluorescence
spectra obtained was used to quantify the VLPs we had produced. The relative fluorescence is
representative of the activity of the -lactamase in this assay which is proportional to the
quantity of each specific VLP present.
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Figure 3. 2nd Quantification of VLPs using -lactamase assay with relative fluorescence.

Description: The preparation of VLPs produced in this study, wtRIG-I VP40 + GP, muRIG-G
VP40 + GP, FLAG VP40 + GP, and wtRIG-I VP40 + GPF88A was repeated and were added in
15 L, 15 L, 20 L, and 30 L increments, respectively, to a black, clear bottom microplate
along with a blank solution (PBS/cytobuster-Fluoricillin solution). The plate was read at a
wavelength of 525 nm and an excitation of 495 nm. The plate was also set to shake on medium
speed before the first read for 8 seconds. Fluorescence spectra was taken above at 0, 2, 60, 210,
and 1140 minutes time post-incubation at room temperature using the USB:SpectraMax i3X
software (Molecular Devices, San Jose, CA, USA). The fluorescence spectra obtained was used
to quantify the VLPs we had produced. The relative fluorescence is representative of the activity
of the -lactamase in this assay which is proportional to the quantity of each specific VLP
present.
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Figure 4. 3rd Quantification of VLPs using -lactamase assay with relative fluorescence

Description: The preparation of VLPs produced in this study, wtRIG-I VP40 + GP, muRIG-G
VP40 + GP, FLAG VP40 + GP, and wtRIG-I VP40 + GPF88A was repeated again and were
added in 20 L, 20 L, 20 L, and 30 L increments, respectively, to a black, clear bottom
microplate along with a blank solution (PBS/cytobuster-Fluoricillin solution). The plate was read
at a wavelength of 525 nm and an excitation of 495 nm. The plate was also set to shake on
medium speed before the first read for 8 seconds. Fluorescence spectra was taken above at 0, 2,
60, 210, and 1140 minutes time post-incubation at room temperature using the USB:SpectraMax
i3X software (Molecular Devices, San Jose, CA, USA). The fluorescence spectra obtained was
used to quantify the VLPs we had produced. The relative fluorescence is representative of the
activity of the -lactamase in this assay which is proportional to the quantity of each specific
VLP present.
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Figure 5. 96-well Plate Layout of Addition of VLPs to Monocytes

Description: Each blood donor was divided into separate wells of triplicates. 25,000 monocytes
were added to each of the colored wells above. Based off of the quantities of VLPs obtained
from -lactamase assay results in Figure 2 above, equivalent amounts of each VLP was added to
their respective well. In each of the wtRIG-I VP40 wells, 10 L of this VLP was added. In each
of the muRIG-I VP40 wells, 9.42 L of this VLP was added. In each of the FLAG VP40 wells,
10.95 L of this VLP was added. In each of the GPF88A wells, 10 L of this VLP was added.
This plate was placed under spinoculation in order to achieve high efficiency of VLP entry into
the monocytes within the wells they were added to. The plate was placed in a 32C incubator for
24 hours.

